ATA3431: Allogeneic CD19/CD20 Bispecific CAR EBV T Cells for the Treatment of B-Cell Malignancies

被引：3
|
作者：
Cha, Seung [1 ]
Charbonneau, Morgan [1 ]
Brito, Alfonso [1 ]
Habibi, Ania [1 ]
Pham, Christina [1 ]
Nguyen, Cokey [1 ]
机构：
[1] Atara Biotherapeut, Thousand Oaks, CA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-181199
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
    Liu, Yanlong
    Ao, Kexin
    Bao, Fuxiang
    Cheng, Yi
    Hao, Yanxia
    Zhang, Huimin
    Fu, Shan
    Xu, Jiaqi
    Wu, Qiyao
    VACCINES, 2022, 10 (08)
  • [22] Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes
    Khvorost, Darya
    Kendall, Brittany
    Jazirehi, Ali R.
    CELLS, 2024, 13 (08)
  • [23] Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment
    Pinto, Navin R.
    Albert, Catherine Michelle
    Taylor, Mallory
    Wilson, Ashley
    Rawlings-Rhea, Stephanie
    Huang, Wenjun
    Seidel, Kristy
    Narayanaswany, Prabha
    Wu, Vicky
    Mgebroff, Stephanie
    Brown, Christopher
    Vitanza, Nicholas A.
    Gardner, Rebecca Alice
    Jensen, Michael C.
    Park, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [24] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma
    Larson, Sarah Marie
    Walthers, Christopher
    Ji, Brenda
    Ghafouri, Sanaz N.
    Naparstek, Jacob
    Trent, Jacqueline
    Harris, Caitlin
    Gandhi, Mobina Khericha
    Schweppe, Thomas
    Auerbach, Martin S.
    Said, Jonathan W.
    Nawaly, Karla
    Mead, Monica Diane
    De Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary J.
    Timmerman, John
    Ribas, Antoni
    Chen, Yvonne Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Phase I Dose-Escalation Trial of CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) T-Cells for the Treatment of Relapsed or Refractory B-Cell Lymphomas and Chronic Lymphocytic Leukemia
    Ghafouri, Sanaz
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Mead, Monica
    Timmerman, John M.
    Chen, Yvonne
    Larson, Sarah
    BLOOD, 2020, 136
  • [26] An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies
    Qi, Junpeng
    Chen, Shih-Shih
    Chiorazzi, Nicholas
    Rader, Christoph
    METHODS, 2019, 154 : 70 - 76
  • [27] Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies
    Shalabi, Haneen
    Martin, Staci
    Yates, Bonnie
    Wolters, Pamela L.
    Kaplan, Claire
    Smith, Hannah
    Sesi, Christopher R.
    Jess, Jennifer
    Toledo-Tamula, Mary Ann
    Struemph, Kari
    Delbrook, Cindy P.
    Khan, Omar, I
    Mackall, Crystal L.
    Lee, Daniel W.
    Shah, Nirali N.
    NEURO-ONCOLOGY, 2022, 24 (09) : 1584 - 1597
  • [28] Production of site-specific allogeneic CD19 CAR-T cells by CRISPR-Cas9 for B-cell malignancies
    Padalia, Zinkal
    Porras, Ashley
    Mu, Dakai
    Lee, Min Jin
    Zhang, Ying
    Huang, Elaine
    Maillet, Ashley
    Li, Jeffrey
    John, Matthias
    Klein, Lawrence
    Lundberg, Sven Ante
    Police, Seshi
    Terrett, Jonathan
    Kalaitzidis, Demetrios
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [29] Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia
    Phely, Laurent
    Hensen, Luca
    Faul, Christoph
    Ruff, Christer Alexander
    Schneider, Dina
    Bethge, Wolfgang Andreas
    Lengerke, Claudia
    JAMA ONCOLOGY, 2024, 10 (06) : 821 - 824
  • [30] Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma (vol 136, pg 1632, 2020)
    Tong, C.
    Zhang, Y.
    Liu, Y.
    Wang, Yao
    Wu, Zhiqiang
    Han, Weidong
    BLOOD, 2023, 141 (15) : 1896 - 1896
12345